The Laboratory of Viromics and Evolution, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, 54531, Republic of Korea.
J Microbiol. 2024 Jul;62(7):491-509. doi: 10.1007/s12275-024-00159-4. Epub 2024 Jul 22.
Adenoviral vectors are crucial for gene therapy and vaccine development, offering a platform for gene delivery into host cells. Since the discovery of adenoviruses, first-generation vectors with limited capacity have evolved to third-generation vectors flacking viral coding sequences, balancing safety and gene-carrying capacity. The applications of adenoviral vectors for gene therapy and anti-viral treatments have expanded through the use of in vitro ligation and homologous recombination, along with gene editing advancements such as CRISPR-Cas9. Current research aims to maintain the efficacy and safety of adenoviral vectors by addressing challenges such as pre-existing immunity against adenoviral vectors and developing new adenoviral vectors from rare adenovirus types and non-human species. In summary, adenoviral vectors have great potential in gene therapy and vaccine development. Through continuous research and technological advancements, these vectors are expected to lead to the development of safer and more effective treatments.
腺病毒载体在基因治疗和疫苗开发中至关重要，为将基因递送到宿主细胞提供了一个平台。自腺病毒被发现以来，第一代容量有限的载体已经进化到第三代载体，缺乏病毒编码序列，在安全性和基因携带能力之间取得了平衡。腺病毒载体在基因治疗和抗病毒治疗中的应用通过体外连接和同源重组以及基因编辑技术（如 CRISPR-Cas9）的进步得到了扩展。目前的研究旨在通过解决针对腺病毒载体的预先存在的免疫和开发来自罕见腺病毒类型和非人类物种的新型腺病毒载体等挑战，来维持腺病毒载体的疗效和安全性。总之，腺病毒载体在基因治疗和疫苗开发方面具有巨大的潜力。通过持续的研究和技术进步，这些载体有望带来更安全、更有效的治疗方法。
